- Home
- SOLV
SOLV
SOLVENTUM CORP
as 12-18-2024 12:43pm EST
Stocks
Solventum Corp is an independent healthcare company with a primary focus on addressing healthcare challenges. Its diverse product portfolio spans the healthcare industry, including medical solutions, oral care, health information systems, and separation and purification sciences.
Upcoming Earnings Alert:
Get ready for potential market movements as SOLVENTUM CORP SOLV prepares to release earnings report on 24 Dec 2024.
| Founded: | 2023 | Country: | United States |
| Employees: | N/A | City: | ST. PAUL |
| Market Cap: | 12.1B | IPO Year: | N/A |
| Target Price: | $68.29 | AVG Volume (30 days): | 801.9K |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 4.16 | EPS Growth: | -47.94 |
| 52 Week Low/High: | $47.16 - $77.17 | Next Earning Date: | 12-24-2024 |
| Revenue: | $8,215,000,000 | Revenue Growth: | 0.60% |
| Revenue Growth (this year): | 2.44% | Revenue Growth (next year): | 0.38% |
Latest SOLVENTUM CORP News
SOLV Breaking Stock News: Dive into SOLV Ticker-Specific Updates for Smart Investing
Investor's Business Daily
2 days ago
Honeywell Mulls A Move That May Herald Aerospace Megamerger
Simply Wall St.
11 days ago
Should You Be Excited About Solventum Corporation's (NYSE:SOLV) 23% Return On Equity?
Argus Research
21 days ago
Analyst Report: Solventum Corp
Argus Research
21 days ago
Market Digest: ADI, CCEP, WBD, SOLV
Argus Research
a month ago
Technical Assessment: Bullish in the Intermediate-Term
PR Newswire
a month ago
Solventum to Participate in the Piper Sandler Healthcare Conference
PR Newswire
a month ago
Solventum Launches First 3D Printed Aligner Attachments to Revolutionize Aligner Treatment
TipRanks
a month ago
Solventum price target raised to $73 from $60 at Morgan Stanley
Compare SOLV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SOLV SOLVENTUM CORP - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.